{"disease":{"id":"advanced-prostate-cancer","name":"advanced prostate cancer"},"drugs":{"marketed":[{"drug_id":"mitoxantrone","indication_name":"Advanced Hormone-Refractory Prostate Cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Novantrone","generic_name":"MITOXANTRONE","company_name":"","drug_phase":"marketed","molecular_target":"Serine/threonine-protein kinase pim-1","drug_class":"Topoisomerase Inhibitor","quality_score":71,"revenue":null,"mechanism":"Novantrone works by interfering with the enzyme topoisomerase, which is necessary for DNA replication and cell division."}],"pipeline":[],"offLabel":[],"totalMarketed":1,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT06825715","title":"Multilevel Intervention for Precision Oncology","phase":"NA","overall_status":"RECRUITING","enrollment_count":2653,"lead_sponsor_name":"VA Office of Research and Development","has_results":false},{"nct_id":"NCT01306890","title":"A Registry of Sipuleucel-T Therapy in Men With Advanced Prostate Cancer","phase":"","overall_status":"COMPLETED","enrollment_count":1976,"lead_sponsor_name":"Dendreon","has_results":true},{"nct_id":"NCT07426094","title":"PRO-BOOST-N: Prostate-First Versus Combined Prostate and Nodal Dose Escalation in PSMA PET-Staged Node-Positive Prostate Cancer","phase":"PHASE2, PHASE3","overall_status":"RECRUITING","enrollment_count":1600,"lead_sponsor_name":"Affidea Nu-med Center of Oncological DIagnostics and Therapy","has_results":false},{"nct_id":"NCT07343349","title":"Addition of Focal Boost to Primary Radiotherapy for Prostate Cancer in 12 or 20 Fractions","phase":"NA","overall_status":"RECRUITING","enrollment_count":1016,"lead_sponsor_name":"Rigshospitalet, Denmark","has_results":false},{"nct_id":"NCT05406999","title":"Neoadjuvant Intense Endocrine Therapy for High Risk and Locally Advanced Prostate Cancer","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":900,"lead_sponsor_name":"The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School","has_results":false},{"nct_id":"NCT06172478","title":"A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":740,"lead_sponsor_name":"Daiichi Sankyo","has_results":false},{"nct_id":"NCT04140526","title":"Safety, PK and Efficacy of ONC-392 in Monotherapy and in Combination of Anti-PD-1 in Advanced Solid Tumors and NSCLC","phase":"PHASE1, PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":733,"lead_sponsor_name":"OncoC4, Inc.","has_results":false},{"nct_id":"NCT07004582","title":"Lab Research Using Mini-tumors to Study Prostate Cancer Treatments","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":600,"lead_sponsor_name":"Maastricht Radiation Oncology","has_results":false},{"nct_id":"NCT06866782","title":"European Registry of Next Generation Imaging in Advanced Prostate Cancer","phase":"","overall_status":"RECRUITING","enrollment_count":600,"lead_sponsor_name":"Fundacio Puigvert","has_results":false},{"nct_id":"NCT05919264","title":"FOG-001 in Locally Advanced or Metastatic Solid Tumors","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":595,"lead_sponsor_name":"Parabilis Medicines, Inc.","has_results":false},{"nct_id":"NCT00942331","title":"Gemcitabine Hydrochloride and Cisplatin With or Without Bevacizumab in Treating Patients With Advanced Urinary Tract Cancer","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":506,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":true},{"nct_id":"NCT05009290","title":"A Trial of SHR3680 in Prostate Cancer Patients Who Are Candidates for Radical Prostatectomy","phase":"PHASE3","overall_status":"TERMINATED","enrollment_count":391,"lead_sponsor_name":"Jiangsu HengRui Medicine Co., Ltd.","has_results":false},{"nct_id":"NCT04606446","title":"Study of PF-07248144 in Advanced or Metastatic Solid Tumors","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":320,"lead_sponsor_name":"Pfizer","has_results":false},{"nct_id":"NCT03193060","title":"A Multi-centre, Prospective, Observational Study on Effectiveness and Safety of ZOLADEX® (Goserelin Acetate Implant) 10.8 mg and ZOLADEX® (Goserelin Acetate Implant) 3.6 mg in Chinese Patients With Localized or Locally Advanced Hormonal Treatment -naïve Prostate Cancer","phase":"","overall_status":"COMPLETED","enrollment_count":308,"lead_sponsor_name":"AstraZeneca","has_results":false},{"nct_id":"NCT06977906","title":"Improved Robotic-Assisted Radical Prostatectomy for Locally Advanced Prostate Cancer: Bladder Suspension and Preliminary Outcomes","phase":"NA","overall_status":"RECRUITING","enrollment_count":300,"lead_sponsor_name":"First Affiliated Hospital of Fujian Medical University","has_results":false},{"nct_id":"NCT04585750","title":"The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":300,"lead_sponsor_name":"PMV Pharmaceuticals, Inc","has_results":false},{"nct_id":"NCT04104776","title":"A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":275,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":false},{"nct_id":"NCT06095089","title":"A Study of JNJ-87189401 Plus JNJ-78278343 for Advanced Prostate Cancer","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":250,"lead_sponsor_name":"Janssen Research & Development, LLC","has_results":false},{"nct_id":"NCT06545942","title":"Study of Orally Administered MOMA-313 in Participants With Advanced or Metastatic Solid Tumors","phase":"PHASE1","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":220,"lead_sponsor_name":"MOMA Therapeutics","has_results":false},{"nct_id":"NCT07570966","title":"Study of ERW316 as a Single Agent or in Combination With Endocrine Therapy in Patients With HR+/HER2- Breast Cancer and Other Advanced Solid Tumors","phase":"PHASE1, PHASE2","overall_status":"NOT_YET_RECRUITING","enrollment_count":217,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":false},{"nct_id":"NCT05800665","title":"A Study Evaluating the Safety, Pharmacokinetics, and Activity of RO7656594 In Participants With Advanced or Metastatic Prostate Cancer","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":210,"lead_sponsor_name":"Genentech, Inc.","has_results":false},{"nct_id":"NCT05869682","title":"Bright White Light Therapy in Reducing Cancer-Related Fatigue and Depression in Advanced Prostate Cancer Patients Undergoing Treatment With ADT Combination Therapy","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":210,"lead_sponsor_name":"City of Hope Medical Center","has_results":false},{"nct_id":"NCT07288359","title":"Study of GVV858 as a Single Agent or in Combination With Endocrine Therapy in Patients With HR+/HER2- Breast Cancer and Other Advanced Solid Tumors","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":205,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":false},{"nct_id":"NCT04742959","title":"Study of TT-00420 (Tinengotinib) Tablet as Monotherapy and Combination Therapy in Patients With Advanced Solid Tumors","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":203,"lead_sponsor_name":"TransThera Sciences (Nanjing), Inc.","has_results":false},{"nct_id":"NCT02155998","title":"Non-Interventional Study PREVENT","phase":"","overall_status":"COMPLETED","enrollment_count":200,"lead_sponsor_name":"AstraZeneca","has_results":false},{"nct_id":"NCT06217822","title":"First-in-human Study of 225Ac-PSMA-Trillium (BAY 3563254) in Participants With Advanced Metastatic Castration-resistant Prostate Cancer (mCRPC)","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":198,"lead_sponsor_name":"Bayer","has_results":false},{"nct_id":"NCT05590793","title":"Effects of Triptorelin Pamoate 6-month When Given to Adult Chinese Participants With Advanced Cancer in the Prostate","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":195,"lead_sponsor_name":"Ipsen","has_results":true},{"nct_id":"NCT06784193","title":"Phase 1 Study of OP-3136 in Advanced or Metastatic Solid Tumors","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":180,"lead_sponsor_name":"Olema Pharmaceuticals, Inc.","has_results":false},{"nct_id":"NCT03217747","title":"Avelumab, Utomilumab, Anti-OX40 Antibody PF-04518600, and Radiation Therapy in Treating Patients With Advanced Malignancies","phase":"PHASE1, PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":173,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":true},{"nct_id":"NCT06769425","title":"HS-10502 Combination Treatment in Patients With Advanced Solid Tumors","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":157,"lead_sponsor_name":"Jiangsu Hansoh Pharmaceutical Co., Ltd.","has_results":false},{"nct_id":"NCT06490328","title":"Efficacy and Safety of DKF-MA102 in Patients With Prostate Cancer","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":154,"lead_sponsor_name":"Dongkook Pharmaceutical Co., Ltd.","has_results":false},{"nct_id":"NCT01884285","title":"AZD8186 First Time In Patient Ascending Dose Study","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":147,"lead_sponsor_name":"AstraZeneca","has_results":false},{"nct_id":"NCT03729596","title":"MGC018 With or Without MGA012 in Advanced Solid Tumors","phase":"PHASE1, PHASE2","overall_status":"TERMINATED","enrollment_count":143,"lead_sponsor_name":"MacroGenics","has_results":true},{"nct_id":"NCT06984159","title":"The Study Will Evaluate if Leuprolide Mesylate is Safe and Effective in the Treatment of Subjects With Advanced Prostate Carcinoma, When Administered as Two Injections Six Months Apart.","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":137,"lead_sponsor_name":"Changchun GeneScience Pharmaceutical Co., Ltd.","has_results":false},{"nct_id":"NCT07038369","title":"A Phase 1 Study of ATV-1601 in Patients With Advanced Cancer That Have AKT1 E17K Mutations","phase":"PHASE1","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":134,"lead_sponsor_name":"Atavistik Bio, Inc","has_results":false},{"nct_id":"NCT03518606","title":"Metronomic Oral Vinorelbine Plus Anti-PD-L1/Anti-CTLA4 ImmunothErapy in Patients With Advanced Solid Tumours","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":126,"lead_sponsor_name":"UNICANCER","has_results":false},{"nct_id":"NCT07080242","title":"Evaluating BL-M14D1 in Subjects With Locally Advanced or Metastatic Small Cell Lung Cancer and Neuroendocrine Tumors","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":120,"lead_sponsor_name":"SystImmune Inc.","has_results":false},{"nct_id":"NCT03938649","title":"SRAM study_Postate Cancer","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":120,"lead_sponsor_name":"CCTU","has_results":false},{"nct_id":"NCT01286987","title":"Study of Talazoparib, a PARP Inhibitor, in Patients With Advanced or Recurrent Solid Tumors","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":113,"lead_sponsor_name":"Pfizer","has_results":true},{"nct_id":"NCT03577028","title":"Study of HPN424 in Patients With Advanced Prostate Cancer","phase":"PHASE1, PHASE2","overall_status":"TERMINATED","enrollment_count":104,"lead_sponsor_name":"Harpoon Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)","has_results":true},{"nct_id":"NCT03701659","title":"TUPKRP Combined With MAB Therapy for LUTS/PCa","phase":"NA","overall_status":"UNKNOWN","enrollment_count":100,"lead_sponsor_name":"The Third Xiangya Hospital of Central South University","has_results":false},{"nct_id":"NCT05942001","title":"Study of HRS-5041 in Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC)","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":100,"lead_sponsor_name":"Jiangsu HengRui Medicine Co., Ltd.","has_results":false},{"nct_id":"NCT03651271","title":"Nivolumab With or Without Ipilimumab in Advanced Metastatic Cancer","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":100,"lead_sponsor_name":"Parker Institute for Cancer Immunotherapy","has_results":true},{"nct_id":"NCT03936218","title":"Goserelin 10.8mg Injection in Treatment of Advanced Prostate Cancer","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":94,"lead_sponsor_name":"Eurofarma Laboratorios S.A.","has_results":false},{"nct_id":"NCT05888532","title":"64Cu-GRIP B in Patients With Advanced Malignancies","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":91,"lead_sponsor_name":"Rahul Aggarwal","has_results":false},{"nct_id":"NCT03682289","title":"Ceralasertib (AZD6738) Alone and in Combination With Olaparib or Durvalumab in Patients With Solid Tumors","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":89,"lead_sponsor_name":"Rahul Aggarwal","has_results":false},{"nct_id":"NCT03350529","title":"MRI Guided Transurethral HIFU for Various Prostate Diseases","phase":"NA","overall_status":"COMPLETED","enrollment_count":87,"lead_sponsor_name":"Turku University Hospital","has_results":false},{"nct_id":"NCT07410494","title":"Biomarker-Guided Allogeneic Single-Target or Dual-Target CAR-NK Cell Therapy for Advanced Solid Tumors","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":85,"lead_sponsor_name":"Essen Biotech","has_results":false},{"nct_id":"NCT05253053","title":"To Evaluate Efficacy and Safety of TT-00420 (Tinengotinib) as Monotherapy and Combination Therapy in Patients With Advanced Solid Tumors","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":84,"lead_sponsor_name":"TransThera Sciences (Nanjing), Inc.","has_results":false},{"nct_id":"NCT06609005","title":"A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity of INV-9956 in Adult Patients With Advanced Metastatic Castration Resistant Prostate Cancer","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":84,"lead_sponsor_name":"Shenzhen Ionova Life Sciences Co., Ltd.","has_results":false}],"total":50},"guidelines":[{"drug_id":"relugolix","guideline_body":"FDA label","recommendation":"ORGOVYX is indicated for the treatment of adult patients with advanced prostate cancer.","line_of_therapy":"1L","evidence_grade":"A","guideline_year":null}],"source":"Drug Landscape verified database"}